Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
Proof of Concept Study for a New Indication of Oral Insulin Capsule for Type 1 Diabetics
JERUSALEM, September 14, 2010/PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) announced today successful results in an exploratory clinical trial testing the effectiveness of its oral insulin capsule (ORMD-0801) in Type I diabetes patients suffering from uncontrolled diabetes.
In parallel to Oramed's main focus in developing an oral insulin
capsule for management of Type II diabetes the company is exploring
an application of its oral insulin capsule toward cases of
uncontrolled Type I diabetics. Unstable or labile diabetes is
characterized by recurrent, unpredictable and dramatic blood
glucose swings often linked with irregular hyperglycemia and
sometimes serious hypoglycemia affecting Type I diabetes patients.
This newly completed exploratory study was a proof of concept study
for defining a novel indication for ORMD-0801. The encouraging
results justify further clinical development of ORMD-0801 capsule
application toward management of uncontrolled diabetes.
"This study marks an impressive milestone for Oramed," says Nadav
Kidron, CEO of Oramed Pharmaceuticals. "These results suggest a
possible novel and unique indication for our oral insulin product
in the treatment of Type I diabetes in addition to our main
indication for Type II diabetes."
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via
injection. Oramed is seeking to revolutionize the treatment of
diabetes through its patented flagship product, an orally
ingestible insulin capsule currently in Phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years
of research performed by top research scientists at Jerusalem's
Hadassah Medical Center. The Company's corporate and R&D
headquarters are based in Jerusalem.
For more information, please visit http://www.oramed.com.
Safe Harbor Statement
Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the
progress, timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company's
ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please
refer to the company's filings with the Securities and Exchange
Commission for a comprehensive list of risk factors that could
cause actual results, performance or achievements of the company to
differ materially from those expressed or implied in such forward
looking statements. The company undertakes no obligation to update
or revise any forward-looking statements.
Company and Investor Relation Contacts:
Oramed Pharmaceuticals Inc.
Tara Horn
Office: +1-646-240-4193
Cell: +972-54-334-4318
Email: tara@oramed.com
Source: Oramed Pharmaceticals
Company and Investor Relation Contacts: Oramed Pharmaceuticals Inc., Tara Horn, Office: +1-646-240-4193, Cell: +972-54-334-4318, Email: tara@oramed.com
Posted: September 2010
